| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Nuclear Medicine and Medical Oncology, Hospital de Sant Pau, Barcelona, Spain
Correspondence: For correspondence or reprints contact: Ignasi Carrió, MD, Nuclear Medicine Unit, Hospital de Sant Pau, Pare Claret 167, 08025 Barcelona, Spain.
ABSTRACT
To assess myocardial cell damage due to doxorubicin cardiotoxicity, we prospectively studied 30 patients with sarcomas who were receiving chemotherapy, including doxorubicin. Sixteen patients were treated by continuous infusion over 72 hr and 14 patients were treated by bolus injection. Antimyosin studies and left ventricular rejection fraction (LVEF) measurements were performed before chemotherapy and at intermediate and maximal cumulative doses. Myocardial antimyosin uptake was quantified by a heart-to-lung ratio (HLR). Myocardial antimyosin uptake was observed in all patients at 240–300 mg/m2 when ejection fraction was still maintained. Seven patients presented with a decrease of 
10% in absolute ejection fraction units at 420–600 mg/m2. Five of these patients had mild congestive heart failure. All patients who presented with a decrease in LVEF 10% at 420–600 mg/m2 had increased antimyosin uptake with HLR 1.90 at a cumulative dose of 240–300 mg/m2. Patients were treated with continuous infusion had less antimyosin uptake than those who were treated with, bolus administration (mean HLR of 1.70 ± 0.09 versus HLR of 2.01 ± 0.16 at a cumulative dose of 240–300 mg/m2, p < 0.01; HLR of 1.86 ± 0.12 versus HLR of 2.32 ± 0.34 at a cumulative dose of 420–600 mg/m2, < 0.01). Two of 16 patients treated by continuous infusion and 5 of 14 patients treated by bolus injection presented with a decrease in ejection fraction 10%. LVEF after chemotherapy in the infusion group was 56% ± 5% and 48% ± 8% (p < 0.05) in the bolus group. Antimyosin studies are helpful in the assessment of doxorubicin cardiotoxicity. Intense antimyosin uptake at intermediate cumulative doses identifies patients at risk of cardiotoxicity before ejection fraction deteriorates. Patients with sarcomas treated by continuous infusion present with less antimyosin uptake than those treated with bolus injection, indicating less severe cardiotoxicity.
This article has been cited by other articles:
|
|
 |
|
  M. E. R. Martin, J. L. Moya-Mur, M. Casanova, A. Crespo-Diez, E. Asin-Cardiel, J. M. Castro-Beiras, L. Diez-Jimenez, M. Ballester, I. Carrio, and J. Narula Role of Noninvasive Antimyosin Imaging in Infants and Children with Clinically Suspected Myocarditis J. Nucl. Med., March 1, 2004; 45(3): 429 - 437. [Abstract] [Full Text]
|
|
|
|
 |
|
 I. Goethals, O. De Winter, P. De Bondt, J. De Sutter, R. Dierckx, and C. Van De Wiele The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage Ann. Onc., September 1, 2002; 13(9): 1331 - 1339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pons-Llado, M. Ballester, X. Borras, F. Carreras, I. Carrio, J. Lopez-Contreras, A. Roca-Cusachs, J. Marrugat, and J. Narula Myocardial cell damage in human hypertension J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2198 - 2203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.C.M. Kremer, M.M.C. Tiel-van Buul, M.C. Ubbink, M. Offringa, J. Ottenkamp, R. V. Olmos, and P.A. Voute Indium-111-Antimyosin Scintigraphy in the Early Detection of Heart Damage After Anthracycline Therapy in Children J. Clin. Oncol., April 1, 1999; 17(4): 1208 - 1208. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
